Abstract Body

Bi-monthly Cabotegravir long-acting (CAB LA) is expected to soon be available as a new option for HIV prevention. Biodegradable in situ forming implants (ISFI) releasing CAB represent an attractive ultra-long-acting delivery platform that can provide sustained drug release for several months to years but can be removed to terminate treatment if needed. We evaluated drug release, drug tail after removal, and PrEP efficacy of CAB ISFIs in macaques

Two 1-ml injections of CAB ISFI (450 mg/mL CAB) were administered in the back to 6 rhesus macaques. CAB concentrations in plasma were monitored weekly for up to 6 months and in tissues every 4 weeks for up to 3 months. Implants were retrieved at week 12 in two animals to assess drug tail after implant removal. Efficacy of CAB ISFIs against rectal SHIV infection was evaluated in 4 macaques using a repeat exposure SHIV transmission model. Macaques were challenged with SHIV162p3 twice a week between weeks 4 thru 8 (n=2 macaques) or weeks 12 thru 16 (n=2 macaques) to assess durability of PrEP efficacy. Two untreated macaques were used as controls. ISFI injection sites (n=2 per animal) were monitored weekly for presence of local skin reactions including edema and erythema

Median (range) plasma CAB levels at weeks 4 and 8 were 982 (406-1,977) and 1,950 (578-5,628) ng/mL, respectively, or about 1.5-3.5-fold higher than the benchmark concentration of 664 ng/ml (4xPA-IC90). Implant removal in 2 macaques at week 12 resulted in a rapid decline in plasma CAB levels from a mean of 2,128 to 179 ng/ml within 3 days. In the remaining animals, median plasma CAB concentrations between weeks 12-24 were 2,136 (971-2,553) ng/mL and remained ~1.9-fold above the 4x PA-IC90 6 months post implantation. CAB concentrations in vaginal and rectal tissues ranged between 293-849 and 333-1,004 ng/g of tissue, respectively (Table 1). In contrast to the 2 untreated animals that were infected after one SHIV challenge, none of the 4 treated macaques were infected after a total of 32 SHIV exposures. No skin reactions were observed at the implant sites in any of the animals

CAB ISFIs implants provided sustained release of CAB above established PrEP benchmarks for up to 6 months and conferred durable protection against SHIV infection in macaques. Implants were safe and resulted in a short drug tail upon removal. Our study describes a novel biodegradable and removable CAB formulation for long-acting PrEP and supports clinical advancement in humans